Carbetocin (United States: Not available): Drug information

(For additional information see "Carbetocin (United States: Not available): Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)

Brand Names: Canada

Duratocin

Pharmacologic Category

Oxytocic Agent

Dosing: Adult

Postpartum hemorrhage, prevention

Postpartum hemorrhage, prevention:

Following vaginal delivery: IV, IM: 100 mcg (single dose only).

Following cesarean section: IV: 100 mcg (single dose only).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Cardiovascular: Flushing (2% to 25%), hypotension (2% to 21%)

Gastrointestinal: Abdominal pain (40%), nausea (3% to 27%)

Hematologic: Anemia (23%)

Nervous system: Headache (13% to 26%), localized warm feeling (19%)

Neuromuscular & skeletal: Tremor (1% to 12%)

1% to 10%:

Cardiovascular: Chest pain (4%), tachycardia (1%)

Dermatologic: Diaphoresis (1%), pruritus (10%)

Gastrointestinal: Metallic taste (1% to 6%), vomiting (3% to 8%)

Nervous system: Anxiety, chills, dizziness (1% to 4%), pain (4%)

Neuromuscular & skeletal: Back pain (4%)

Respiratory: Dyspnea (1% to 10%)

Miscellaneous: Fever (9%)

Contraindications

Hypersensitivity to carbetocin, oxytocin, or any component of the formulation; administration prior to delivery of infant for any reason (including elective or medical induction of labor); serious cardiovascular disorders; use in children

Warnings/Precautions

Concerns related to adverse effects:

• Antidiuretic effect: May produce antidiuretic effect; risk of water intoxication cannot be excluded.

• Bleeding: Persistent bleeding warrants further evaluation to rule out coagulopathy, genital tract trauma, or the presence of retained placental fragments.

Disease-related concerns:

• Asthma: Use with caution in patients with asthma.

• Cardiovascular disease: Use has not been studied in patients with known coagulopathy; use with extreme caution in patients with cardiovascular disease (contraindicated in serious cardiovascular disorders), especially coronary artery disease.

• Epilepsy: Use with caution in patients with epilepsy.

• Migraines: Use with caution in patients with migraines.

Other warnings/precautions:

• Appropriate use: Carbetocin induced contractions are of a longer duration than those observed with oxytocin and are not stopped by discontinuation of therapy. Improper use during pregnancy may produce symptoms similar to those observed with oxytocin overdosage (eg, hyperstimulation of uterus with strong or prolonged contractions, tumultuous labor, uterine rupture, cervical and vaginal lacerations, postpartum hemorrhage, utero-placental hypoperfusion and variable deceleration of fetal heart rate, fetal hypoxia, hypercapnia, or death). Therapy should not be repeated if response to initial dose is inadequate; aggressive therapy with alternative agents (eg, oxytocin, ergonovine) should be utilized.

Product Availability

Not available in the US

Generic Equivalent Available: US

Yes

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Injection:

Duratocin: 100 mcg/mL (1 mL)

Solution, Intravenous:

Duratocin: 100 mcg/mL ([DSC])

Generic: 100 mcg/mL (1 mL)

Administration: Adult

IV: Administer undiluted as bolus IV injection over 1 minute. Following vaginal delivery, administer as soon as possible after delivery of the infant, preferably before delivery of the placenta. Following cesarean section, administer only after delivery of infant has been completed by cesarean section; may administer before or after delivery of placenta.

IM: IM administration may also be used following vaginal delivery only.

Use: Labeled Indications

Note: Not approved in the US.

Postpartum hemorrhage, prevention: Prevention of postpartum hemorrhage by controlling uterine atony.

Medication Safety Issues

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes oxytocin (carbetocin analog) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine. Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine. Risk D: Consider therapy modification

Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk). Risk C: Monitor therapy

Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents. Risk C: Monitor therapy

Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). Risk C: Monitor therapy

Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Azithromycin (Systemic): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Azithromycin (Systemic). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents. Risk C: Monitor therapy

Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Risk X: Avoid combination

Carboprost Tromethamine: May enhance the adverse/toxic effect of Oxytocic Agents. Specifically, oxytocic effects may be enhanced. Risk X: Avoid combination

Chloroquine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Chloroquine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Clofazimine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Clofazimine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Dabrafenib: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Dabrafenib. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Dinoprostone: May enhance the adverse/toxic effect of Carbetocin. Specifically, Carbetocin oxytocic effects may be enhanced. Risk X: Avoid combination

Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. Risk C: Monitor therapy

Encorafenib: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Fexinidazole: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Fluorouracil Products: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Gadobenate Dimeglumine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Gadobenate Dimeglumine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Halofantrine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Halofantrine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Haloperidol: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Haloperidol. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. Risk C: Monitor therapy

Inotuzumab Ozogamicin: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Inotuzumab Ozogamicin. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. Risk C: Monitor therapy

Levoketoconazole: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole. Risk X: Avoid combination

Lofexidine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Lofexidine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Midostaurin: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Midostaurin. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

MiSOPROStol: May enhance the adverse/toxic effect of Carbetocin. Specifically, Carbetocin oxytocic effects may be enhanced. Risk X: Avoid combination

Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. Risk C: Monitor therapy

Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion. Risk D: Consider therapy modification

Ondansetron: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Ondansetron. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Pentamidine (Systemic): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Pentamidine (Systemic). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. Risk C: Monitor therapy

Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk). Risk X: Avoid combination

Piperaquine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Piperaquine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Probucol: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Probucol. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

QT-prolonging Agents (Highest Risk): Carbetocin may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

QT-prolonging Antidepressants (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

QT-prolonging Class IC Antiarrhythmics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Class IC Antiarrhythmics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

QT-Prolonging Inhalational Anesthetics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

QT-prolonging Kinase Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

QT-prolonging Miscellaneous Agents (Moderate Risk): May enhance the QTc-prolonging effect of Carbetocin. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

QT-prolonging Quinolone Antibiotics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk). Risk X: Avoid combination

Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Toremifene: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Toremifene. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Pregnancy Considerations

Carbetocin is indicated for the prevention of postpartum hemorrhage following vaginal or cesarean delivery; use prior to delivery is contraindicated.

Carbetocin induced contractions are of a longer duration than those observed with oxytocin and are not stopped by discontinuation of therapy. Improper use during pregnancy may produce symptoms similar to those observed with oxytocin overdosage (eg, hyperstimulation of uterus, uterine rupture).

Breastfeeding Considerations

Carbetocin is present in breast milk.

Carbetocin was detected in the breast milk of 5 healthy breastfeeding women ~7 to 14 weeks postpartum though peak levels observed were 50 times lower than in plasma (Silcox 1993). Exposure to the breastfeeding infant is expected to be minimal and not expected to pose significant health risks as carbetocin in breast milk is rapidly degraded in the GI tract of a breastfeeding infant.

Milk let-down occurred normally in 5 breastfeeding women following a dose of carbetocin 70 mcg IM.

Monitoring Parameters

Heart rate, BP, blood loss, temperature (FIGO [Escobar 2022]).

Mechanism of Action

Binds oxytocin receptors located in uterine smooth muscle producing rhythmic uterine contractions characteristic to deliver, as well as increasing both the frequency of existing contractions and uterine tone. Enhances uterine involution early in postpartum.

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: IV: 1.2 ± 0.5 minutes.

Distribution: V_d: 22 L.

Bioavailability: IM: 77%.

Duration: IV: ~60 minutes; IM: ~120 minutes (Sweeney 1990; WHO 2018).

Half-life elimination: Terminal: IV: 33 minutes; IM: 55 minutes.

Time to peak: IM: 30 minutes (median).

Excretion: IV: Urine (<1%, as unchanged drug).

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AE) United Arab Emirates: Pabal;
(AR) Argentina: Duratocin | Laetis;
(AT) Austria: Pabal;
(AU) Australia: Duratocin;
(BE) Belgium: Pabal;
(CH) Switzerland: Pabal;
(CN) China: Duratocin;
(CZ) Czech Republic: Duratocin | Karbetocin avmc;
(DE) Germany: Pabal;
(EC) Ecuador: Duratocin;
(EE) Estonia: Carbetocin auxilia | Pabal;
(EG) Egypt: Pabal;
(ES) Spain: Duratobal;
(FI) Finland: Pabal;
(FR) France: Pabal;
(GB) United Kingdom: Pabal;
(GR) Greece: Pabal;
(HU) Hungary: Pabal;
(ID) Indonesia: Pabal;
(IE) Ireland: Pabal;
(IN) India: Carbecin | Carbitex;
(IT) Italy: Duratocin;
(JO) Jordan: Pabal;
(KE) Kenya: Pabal;
(KR) Korea, Republic of: Duratocin | Duratocin rts;
(KW) Kuwait: Pabal;
(LB) Lebanon: Pabal;
(LT) Lithuania: Pabal;
(LV) Latvia: Pabal;
(MX) Mexico: Dankistol | Pisparhem;
(MY) Malaysia: Duratocin;
(NG) Nigeria: Pabal;
(NL) Netherlands: Pabal;
(NO) Norway: Pabal;
(NZ) New Zealand: Duratocin;
(PE) Peru: Duratocin;
(PH) Philippines: Duratocin;
(PL) Poland: Pabal;
(PY) Paraguay: Duratocin;
(QA) Qatar: Pabal;
(RU) Russian Federation: Pabal;
(SA) Saudi Arabia: Pabal;
(SE) Sweden: Pabal;
(SG) Singapore: Duratocin;
(SI) Slovenia: Pabal;
(SK) Slovakia: Pabal;
(TH) Thailand: Duratocin;
(TR) Turkey: Pabal;
(TW) Taiwan: Duratocin;
(UA) Ukraine: Carbetocinum;
(UG) Uganda: Pabal;
(UY) Uruguay: Duratocin;
(ZA) South Africa: Pabal

Borruto F, Treisser A, and Comparetto C, “Utilization of Carbetocin for Prevention of Postpartum Hemorrhage After Cesarean Section: A Randomized Clinical Trial,” Arch Gynecol Obstet, 2009, 280(5):707-12. [PubMed 19229549]
Dansereau J, Joshi AK, Helewa ME, et al, “Double-Blind Comparison of Carbetocin Versus Oxytocin in Prevention of Uterine Atony After Cesarean Section,” Am J Obstet Gynecol, 1999, 180(3 Pt 1):670-6. [PubMed 10076146]
Duratocin (carbetocin) ampoule [product monograph]. North York, Ontario, Canada: Ferring Inc; April 2020.
Duratocin (carbetocin) [product monograph]. North York, Ontario, Canada: Ferring Inc; March 2022.
Escobar MF, Nassar AH, Theron G, et al; FIGO Safe Motherhood and Newborn Health Committee. FIGO recommendations on the management of postpartum hemorrhage 2022. Int J Gynaecol Obstet. 2022;157(suppl 1):3-50. doi:10.1002/ijgo.14116 [PubMed 35297039]
Robinson D, Basso M, Chan C, Duckitt K, Lett R. Guideline no. 431: postpartum hemorrhage and hemorrhagic shock. J Obstet Gynaecol Can. 2022;44(12):1293-1310.e1. doi:10.1016/j.jogc.2022.10.002 [PubMed 36567097]
Silcox J, Schulz P, Horbay GL, et al, “Transfer of Carbetocin Into Human Breast Milk,” Obstet Gynecol, 1993, 82(3):456-9. [PubMed 8355953]
Sweeney G, Holbrook AM, Levine M, et. al. Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, in nonpregnant women. Current Therapeutic Research - Clinical and Experimental. 1990;47(3):528-540.
World Health Organization (WHO) recommendations. Uterotonics for the prevention of postpartum haemorrhage. Published 2018. https://apps.who.int/iris/bitstream/handle/10665/277276/9789241550420-eng.pdf?ua=1.

Topic 8562 Version 153.0

خرید پکیج

Carbetocin (United States: Not available): Drug information